Get the Stockscreener App
1.63
7.39%
-0.13
After Hours:
1.72
0.09
+5.52%
Aldeyra Therapeutics Inc stock is traded at $1.63, with a volume of 946.33K.
It is down -7.39% in the last 24 hours and down -5.23% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.76
Open:
$1.76
24h Volume:
946.33K
Relative Volume:
0.32
Market Cap:
$98.32M
Revenue:
-
Net Income/Loss:
$-27.37M
P/E Ratio:
-3.5808
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
-6.86%
1M Performance:
-5.23%
6M Performance:
-65.32%
1Y Performance:
-33.47%
1-Day Range:
$1.615
$1.76
1-Week Range:
$1.58
$1.93
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.63 | 106.17M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics eyes FDA feedback as dry eye drug faces make-or-break moment - MSN
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Significant Share Purchase - GuruFocus
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock - Investing.com
Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing - marketscreener.com
Aldeyra (NASDAQ: ALDX) CEO Todd Brady purchases 250,000 common shares - Stock Titan
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment - inkl
3 Promising Penny Stocks With Market Caps Reaching $300M - simplywall.st
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
Aldeyra Therapeutics CEO to Speak at Jefferies Global Healthcare Conference - GuruFocus
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
ALDX Technical Analysis | Trend, Signals & Chart Patterns | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS) - openPR.com
ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Investor Alert: Deadline in Lawsuit on May 29, 2026 - openPR.com
Gossamer Bio, Inc. (NASDAQ: GOSS) Investor Alert: Deadline in Lawsuit on June 1, 2026 - openPR.com
Aldeyra Therapeutics Faces Class Action Deadline Amid FDA Rejections (ALDX) - GuruFocus
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra - GuruFocus
ALDX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Aldeyra Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Amid FDA Rej - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - 巴士的報
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra - GlobeNewswire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
היום המועד האחרון לתביעה ייצוגית נגד ALDX: רוזן, חברה שפתחה בהליכים ראשונה, מעודדת משקיעים ב-Aldeyra Therapeutics, Inc עם הפסדים של יותר מ-100 אלף דולר לקבל ייעוץ משפטי לפני המועד החשוב ב-29 במאי בתביעה ייצוגית לניירות ערך שהוגשה לראשונה על ידי המשרד – ALDX - GlobeNewswire Inc.
B&W DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages - GlobeNewswire
ALDX DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Aldeyra Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - PR Newswire
INVESTOR DEADLINE APPROACHING: Aldeyra Therapeutics (ALDX) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before May 29, 2026 Securities Class Action Deadline - ACCESS Newswire
ALDX INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
2026-05-27 | ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ALDX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - TMX Newsfile
ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, - GlobeNewswire
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Cl - GuruFocus
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Aldeyra Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - PR Newswire
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Aldeyra Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
ALDX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - TMX Newsfile
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Aldeyra Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. ... - Caledonian Record
ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, - GlobeNewswire
ALDX Deadline: ALDX Investors with Losses in Excess of $100K Hav - GuruFocus
ALDX Deadline: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Press releases provided by CNW - Techaeris
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
| Alfieri Michael | Principal Financial Officer |
Aug 13 '25 |
Buy |
5.30 |
2,500 |
13,250 |
2,500 |
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):